Expression and Significance of Nodal in Human Cancers: a Meta-analysis

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2016 Feb 18

PMID 26884935

Citations 5

Authors

Fen Ning

Hai-Fang Wang

Qiang Guo

Zong-Cai Liu

Zi-Qian Li

Jun Du

Affiliations

Soon will be listed here.

Abstract

Cancer is a global and growing problem. Nodal, which has been showed to be involved in occurrence and development of cancers, is an important embryonic morphogen. The aim of this study was to evaluate the significance of Nodal expression in human cancers based on the published related articles. Online databases were searched to retrieve relevant articles published between 2000 and 2015. The odds ratio (OR) with its 95% confident intervals (CI) were employed to calculate the strength of significance. Finally, a total of 11 articles were screened out, including 801 cancer patients and 372 healthy controls. Nine kinds of cancers were contained, and Nodal was detected in 56.7% of all participants (665/1173). Overall, our result found that Nodal was highly expressed in cancer patients than that in healthy controls, indicating that Nodal expression was significantly associated with cancers progression (OR=21.72, 95% CI=9.94-47.46, P<0.00001). Subgroup analysis showed that Nodal expression was significantly corrected with high WHO grade of human cancers (III+IV versus I+II: OR=2.46, 95% CI=1.63-3.71, P<0.00001). This significant relationship was also found in tumor size, differentiation degree, not observed in gender, age and lymphatic metastasis status of patients with all studied cancers in this meta-analysis. In conclusion, our results demonstrated that Nodal might be implicated in cancer progression, suggesting that it was a potential biomarker and therapeutic target for cancers.

Citing Articles

Higher Nodal expression is often associated with poorer survival in patients diagnosed with melanoma and treated with anti-PD1 therapy.

Gascard P, Wang X, Nosrati M, Kim K, Kashani-Sabet M, Tlsty T Pathol Oncol Res. 2024; 30:1611889.

PMID: 39376672 PMC: 11456440. DOI: 10.3389/pore.2024.1611889.

New Insights into Cancer Targeted Therapy: Nodal and Cripto-1 as Attractive Candidates.

Arboretto P, Cillo M, Leonardi A Int J Mol Sci. 2021; 22(15).

PMID: 34360603 PMC: 8345935. DOI: 10.3390/ijms22157838.

Nodal-induced L1CAM/CXCR4 subpopulation sustains tumor growth and metastasis in colorectal cancer derived organoids.

Delle Cave D, Hernando-Momblona X, Sevillano M, Minchiotti G, Lonardo E Theranostics. 2021; 11(12):5686-5699.

PMID: 33897875 PMC: 8058729. DOI: 10.7150/thno.54027.

Targeting the untargetable? Nodal expression in TNBC.

Young E, Welch D Cell Cycle. 2016; 15(11):1400.

PMID: 27027858 PMC: 4934075. DOI: 10.1080/15384101.2016.1166816.

Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment.

Bodenstine T, Chandler G, Reed D, Margaryan N, Gilgur A, Atkinson J Cell Cycle. 2016; 15(9):1295-302.

PMID: 27007464 PMC: 4889232. DOI: 10.1080/15384101.2016.1160981.

References

Chen J, Li J, Liu W, Jia W, Xu G, Ma J . [Expression of Nodal in hepatocellular carcinoma and its relationship with angiogenesis and epithelial-mesenchymal transition]. Zhonghua Wai Ke Za Zhi. 2014; 52(3):188-92. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Jung K, Won Y, Kong H, Oh C, Lee D, Lee J . Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014; 46(2):109-23. PMC: 4022819. DOI: 10.4143/crt.2014.46.2.109. View

Chai Y, Kim Y, Jee H, Yi J, Jang B, Lee K . Expression of the embryonic morphogen Nodal in differentiated thyroid carcinomas: Immunohistochemistry assay in tissue microarray and The Cancer Genome Atlas data analysis. Surgery. 2014; 156(6):1559-67. DOI: 10.1016/j.surg.2014.08.050. View

Vanneman M, Dranoff G . Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012; 12(4):237-51. PMC: 3967236. DOI: 10.1038/nrc3237. View

Papageorgiou I, Nicholls P, Wang F, Lackmann M, Makanji Y, Salamonsen L . Expression of nodal signalling components in cycling human endometrium and in endometrial cancer. Reprod Biol Endocrinol. 2009; 7:122. PMC: 2774317. DOI: 10.1186/1477-7827-7-122. View

Kenney N, Adkins H, Sanicola M . Nodal and Cripto-1: embryonic pattern formation genes involved in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2004; 9(2):133-44. DOI: 10.1023/B:JOMG.0000037158.91940.1c. View

Hueng D, Lin G, Huang S, Liu L, Ju D, Chen Y . Inhibition of Nodal suppresses angiogenesis and growth of human gliomas. J Neurooncol. 2010; 104(1):21-31. DOI: 10.1007/s11060-010-0467-3. View

Quail D, Siegers G, Jewer M, Postovit L . Nodal signalling in embryogenesis and tumourigenesis. Int J Biochem Cell Biol. 2013; 45(4):885-98. DOI: 10.1016/j.biocel.2012.12.021. View

10.

Lawrence M, Margaryan N, Loessner D, Collins A, Kerr K, Turner M . Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate. 2011; 71(11):1198-209. PMC: 3234312. DOI: 10.1002/pros.21335. View

11.

Bray F, Jemal A, Grey N, Ferlay J, Forman D . Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012; 13(8):790-801. DOI: 10.1016/S1470-2045(12)70211-5. View

12.

Quail D, Zhang G, Findlay S, Hess D, Postovit L . Nodal promotes invasive phenotypes via a mitogen-activated protein kinase-dependent pathway. Oncogene. 2013; 33(4):461-73. PMC: 5025281. DOI: 10.1038/onc.2012.608. View

13.

Kong B, Wang W, Esposito I, Friess H, Michalski C, Kleeff J . Increased expression of Nodal correlates with reduced patient survival in pancreatic cancer. Pancreatology. 2015; 15(2):156-61. DOI: 10.1016/j.pan.2015.02.001. View

14.

Quail D, Zhang G, Walsh L, Siegers G, Dieters-Castator D, Findlay S . Embryonic morphogen nodal promotes breast cancer growth and progression. PLoS One. 2012; 7(11):e48237. PMC: 3492336. DOI: 10.1371/journal.pone.0048237. View

15.

Chen J, Liu W, Jia W, Xu G, Ma J, Ren Y . Embryonic morphogen nodal is associated with progression and poor prognosis of hepatocellular carcinoma. PLoS One. 2014; 9(1):e85840. PMC: 3897529. DOI: 10.1371/journal.pone.0085840. View

16.

Kaminska B, Wesolowska A, Danilkiewicz M . TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol. 2005; 52(2):329-37. View

17.

Duan W, Li R, Ma J, Lei J, Xu Q, Jiang Z . Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Oncotarget. 2015; 6(3):1490-506. PMC: 4359309. DOI: 10.18632/oncotarget.2686. View

18.

Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N . Cancer survival in China, 2003-2005: a population-based study. Int J Cancer. 2014; 136(8):1921-30. DOI: 10.1002/ijc.29227. View

19.

Strizzi L, Hardy K, Margaryan N, Hillman D, Seftor E, Chen B . Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res. 2012; 14(3):R75. PMC: 3446338. DOI: 10.1186/bcr3185. View

20.

Mfopou J, Chen B, Sui L, Sermon K, Bouwens L . Recent advances and prospects in the differentiation of pancreatic cells from human embryonic stem cells. Diabetes. 2010; 59(9):2094-101. PMC: 2927928. DOI: 10.2337/db10-0439. View